{
    "clinical_study": {
        "@rank": "114388", 
        "arm_group": [
            {
                "arm_group_label": "Levobupivacaine", 
                "arm_group_type": "Experimental", 
                "description": "Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride\nIndication: production of subarachnoid block (spinal/ spinal anesthesia)."
            }, 
            {
                "arm_group_label": "Bupivacaine", 
                "arm_group_type": "Active Comparator", 
                "description": "Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride\nIndication: production of subarachnoid block (spinal/ spinal anesthesia)."
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical trial phase III, noninferiority, controlled, double-blind, randomized. The purpose\n      of this study is to evaluate the noninferiority between Levobupivacaine and Bupivacaine in\n      spinal anesthesia."
        }, 
        "brief_title": "Phase III, Evaluate Noninferiority Between Levobupivacaine and Bupivacaine in Spinal Anesthesia.", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Orthopedic Disorder of Spine.", 
        "condition_browse": {
            "mesh_term": "Spinal Diseases"
        }, 
        "detailed_description": {
            "textblock": "Objectives:\n\n      Primary:\n\n        -  Evaluation of latency to sensory block of T10.\n\n        -  Evaluation of the duration of sensory block.\n\n      Secondary:\n\n        -  Evaluation of the motor block degree.\n\n        -  Evaluation of motor block duration.\n\n        -  Evaluation of cardiovascular safety.\n\n        -  Block failure.\n\n        -  Observation of adverse events.\n\n      Study Plan:\n\n        -  Estimated 120 research participants;\n\n        -  Aged between 18 - 80 in both gender;\n\n        -  Drug Intervention: 01 day\n\n      Evaluations during Trial:\n\n        -  Classification of anesthetic risk: Class I to VI by the American Society of\n           Anesthesiologists(ASA);\n\n        -  Identification of the Anesthetic Failure;\n\n        -  Latency time for sensory block at T10;\n\n        -  Duration of sensory block and motor block;\n\n        -  Bromage scale;\n\n        -  Cardiovascular safety;\n\n      Retention of Records:\n\n      The investigator shall retain all documentation of the study over a period of at least five\n      years from the end of the study. The Sponsor or its designee will provide a list of all\n      documentation which should be kept by the Investigator.\n\n      Monitoring:\n\n      All aspects of the study will be carefully monitored by Crist\u00e1lia Pharmaceutical Chemicals\n      Ltda. or designated representative of it (Clinical Research Organization - CRO) for\n      evaluations related to good clinical practice and applicable local regulations.\n\n      Case Report Forms. The Monitor will be available if the investigator, or other person of his\n      team, needs information and guidance.\n\n      The Monitor of the study should have permanent access to all documentation and it is his\n      obligation to ensure that the Case Report Forms are complete and completed correctly, as\n      well as checking if the data are described according to the source documents, in order to\n      eliminate interferences that may compromise the accuracy of the data generated in the\n      clinical trial.\n\n      Audit and Inspections:\n\n      Authorized representatives of the Sponsor or designees, regulatory authority or the Ethics\n      Committee of the institution may conduct audits or inspections during or after the study\n      conclusion.\n\n      Collecting Data:\n\n      The information corresponding to the data of interest from the study will be collected and\n      recorded in Case Report forms provided by Sponsor, and filled from the information contained\n      in the source documents.\n\n      Documents are considered sources for study: medical records used by the professional at the\n      time of the visits, diagnostic tests or image.\n\n      Informed Consent of Trial:\n\n      The Principal Investigator will ensure that the research participant receive verbally and in\n      writing all relevant information about the nature, purpose, the test drug, the possible\n      risks and benefits of the study.\n\n      Research participants will be notified that they are free to discontinue the study at any\n      time. That they will have the opportunity to ask questions and to have sufficient time to\n      consider the information received.\n\n      Formation of the database:\n\n      The database of the study will be assembled with the data from the Case Report Forms. Doubts\n      and discrepancies will generate questions (queries) written to the Principal Investigator."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients of both sexes;\n\n          -  Age between 18 and 80 years;\n\n          -  Risk anesthetic classified as ASA I or ASA II, according to the American Society of\n             Anesthesiology;\n\n          -  What have indication for spinal orthopedic surgery in the lower limbs;\n\n          -  Have agreed to participate and signed the informed consent form.\n\n        Exclusion Criteria:\n\n          -  Absolute or relative contraindications to spinal anesthesia;\n\n          -  Hypersensitivity or intolerance to local anesthetics or to components of the formula;\n\n          -  Spinal cord injuries, peripheral neuropathy or other neurological condition that lead\n             to sensitivity and/ or motor function disorder;\n\n          -  Dementia, mental retardation and others important cognitive changes;\n\n          -  Obesity with a body mass index ( BMI ) \u2265 35 or difficulty in executing the puncture;\n\n          -  Anatomical column difficulty in the opinion of the investigator;\n\n          -  Previous spine surgical intervention;\n\n          -  Polytrauma;\n\n          -  Tattoo at the puncture site;\n\n          -  Alcoholism;\n\n          -  Abuse of illicit substances;\n\n          -  Antecedents of severe anaphylactic reactions or  Steven - Johnson disease;\n\n          -  Changes in security checks;\n\n          -  Participation in a clinical study in the 12 months preceding this inclusion;\n\n          -  Pregnancy and lactation;\n\n          -  Any other condition that in the opinion of the investigator, may lead to increased\n             risk for the patient."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994967", 
            "org_study_id": "CRT074"
        }, 
        "intervention": [
            {
                "arm_group_label": "Levobupivacaine", 
                "description": "Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.", 
                "intervention_name": "Levobupivacaine", 
                "intervention_type": "Drug", 
                "other_name": "Levobupivacaine Hydrochloride."
            }, 
            {
                "arm_group_label": "Bupivacaine", 
                "description": "Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.", 
                "intervention_name": "Bupivacaine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Neoca\u00edna \u00ae.", 
                    "Bupivacaine Hydrochloride."
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Bupivacaine", 
                "Levobupivacaine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase III", 
            "Noninferiority", 
            "Controlled", 
            "Double-blind", 
            "Randomized", 
            "Spinal", 
            "Anesthetic", 
            "Lower limb"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "contact": {
                "last_name": "On\u00e9simo D. Ribeiro Junior, Medic", 
                "phone": "55 11 4930-4243"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "zip": "09780-000"
                }, 
                "name": "CEMEC - Multidisciplinary Center of Clinical Studies"
            }, 
            "investigator": {
                "last_name": "On\u00e9simo D. Ribeiro Junior, Medic", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study Phase III to Evaluate the Noninferiority of Heavy Levobupivacaine 50% Enantiomeric Excess (Levobupivacaine S75:R25) Compared to Racemic Heavy Bupivacaine (Bupivacaine S50:R50) in Spinal Anesthesia for Lower Limb Orthopedic Procedures", 
        "overall_contact": {
            "email": "cemec.assessoria@gmail.com", 
            "last_name": "On\u00e9simo D. Ribeiro Junior, Medic", 
            "phone": "55 11 4930-4243"
        }, 
        "overall_official": {
            "affiliation": "CEMEC", 
            "last_name": "On\u00e9simo D. Ribeiro Junior, Medic", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The interval of time between the withdrawal of the needle at the end of local anesthetic injection and the absence of response to sensory stimulus in the region corresponding to the T10.", 
                "measure": "Time of latency to achieve sensitive block of T10.", 
                "safety_issue": "No", 
                "time_frame": "01 day."
            }, 
            {
                "description": "Duration of anesthesia as for the sensory aspect through a needle stimulus in the anterior side of the foot.", 
                "measure": "Duration time of the sensory block of T10.", 
                "safety_issue": "No", 
                "time_frame": "01 day."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994967"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ability of the patient to move their lower limbs, assessed by Bromage scale.", 
                "measure": "Sensory block intensity.", 
                "safety_issue": "Yes", 
                "time_frame": "02 days."
            }, 
            {
                "description": "Time interval between the end of anesthetic injection and the return to 0 score in modified Bromage scale.", 
                "measure": "Motor block duration.", 
                "safety_issue": "Yes", 
                "time_frame": "02 days."
            }, 
            {
                "description": "Incidence and severity of hemodynamic (BP and HR) and respiratory (SpO2) alterations.", 
                "measure": "Cardiovascular safety.", 
                "safety_issue": "Yes", 
                "time_frame": "02 days."
            }, 
            {
                "description": "To evaluate the absence of signs of analgesia or motor block for at least 20 minutes after anesthetic injection in the sensitive region studied.", 
                "measure": "Block failure.", 
                "safety_issue": "Yes", 
                "time_frame": "02 days."
            }, 
            {
                "description": "To evaluate the occurrence of adverse events regarding the frequency, duration, severity and causal relationship with the study medication.", 
                "measure": "Adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "02 days."
            }
        ], 
        "source": "Crist\u00e1lia Produtos Qu\u00edmicos Farmac\u00eauticos Ltda.", 
        "sponsors": {
            "collaborator": {
                "agency": "Newco Trials Pesquisa Cient\u00edfica Ltda", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Crist\u00e1lia Produtos Qu\u00edmicos Farmac\u00eauticos Ltda.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}